Acromegaly Treatment Market Size, Share, and Industry Analysis By Drug Type (Somatostatin Analogs, Dopamine Agonists, Growth Hormone Receptor Antagonists, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global acromegaly treatment market size was valued at USD 1.77 billion in 2025. The market is projected to grow from USD 1.89 billion in 2026 to USD 3.13 billion by 2034, exhibiting a CAGR of 6.51% during the forecast period.

Acromegaly is a rare and chronic condition in adults that is triggered by an overproduction of the growth hormone, leading to symptoms such as enlarged hands, feet, and facial features. The primary cause is pituitary adenomas, which leads to an increased growth hormone signals that, in turn, prompts the liver to overproduce an insulin-like growth factor-1 (IGF-1).

Acromegaly can result in cardiovascular, respiratory, musculoskeletal, endocrine, metabolic, and neoplastic comorbidities. Conventionally, the early onset of the disease and clinical manifestations have a significant gap, resulting in various complications. Early detection and appropriate intervention are crucial in reducing the elevated risk of mortality associated with acromegaly. Transsphenoidal pituitary surgery is considered as first-line treatment for pituitary adenomas. However, larger tumors require other therapeutics, such as somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, for the long-term management of acromegaly.

The market for acromegaly treatment is expected to grow considerably in the near future. The rise in awareness of pituitary diseases and advancements in diagnostic tools have potentially led to an early diagnosis in recent years, increasing the prevalence of the disease. The trend of increasing prevalence and emphasis of industry players on introducing new and effective interventions are anticipated to be key drivers of the market. Moreover, the guidelines by regulatory bodies such as the U.S. FDA are anticipated to drive the drug discovery initiatives further and a certain growth in the market is expected in the near future.

• For instance, in January 2023, the U.S. FDA released a draft guidance to aid sponsors in the development of treatments for acromegaly patients who have not responded to surgery or are in poor health.

These guidelines, along with the promising pipelines, are anticipated to signficantly boost the market growth.

The COVID-19 pandemic has had a significant impact on the acromegaly treatment market. The pandemic disrupted healthcare services, including regular doctor visits and surgeries, which has affected the treatment and management of acromegaly.

However, in late 2020, the adoption of telehealth and virtual care solutions facilitated continued access to care for patients with acromegaly and the market witnessed growth. For instance, according to an article published in the Archives of Endocrinology and Metabolism in November 2022, the use of telemedicine for acromegaly increased in Brazil during the pandemic. Overall, the market witnessed growth in 2021 and is anticipated to grow continuously during the study period.

Key Insights

• Prevalence of Acromegaly, By Key Countries/Region, 2023
• Pipeline Analysis
• Overview: Regulatory Scenario, By Key Regions
• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• Impact of COVID-19 on the Market

Segmentation

Analysis by Product Type

Based on product type, the somatostatin analogs segment accounted for a significant share in the global market. Somatostatin analogs are the primary treatment as they inhibit the hormones responsible for acromegaly induction. Various clinical studies showed that somatostatin analogs such as octreotide and lanreotide induce tumor shrinkage in the newly diagnosed acromegaly patients. The clinical benefits of the drug and the growing number of potential drug candidates in the pipeline are anticipated to drive the launch of novel somatostatin analogs, contributing to the segmental growth in the coming years.

• For instance, in September 2023, Crinetics Pharmaceuticals, Inc. announced positive results on oral paltusotine for the treatment of acromegaly. It is a phase three pilot study conducted on patients with acromegaly.

The growth hormone receptor antagonist segment is anticipated to grow considerably over the forecast period. As these drugs block the activity of growth hormones, the use of these drugs is anticipated to rise over the coming years.

Regional Analysis

North America accounted for the largest revenue share in 2022. The region is expected to dominate the acromegaly treatment market due to the high prevalence of acromegaly and the presence of major players. Furthermore, an increase in drug discovery initiatives among key industry players for new formulations and promising drug candidates is expected to enhance regional expansion over the coming years.  

The Asia Pacific region is expected to witness faster growth in the acromegaly treatment market due to the growing awareness about rare diseases such as acromegaly and rising healthcare spending. The increasing prevalence of hormonal disorders, including acromegaly, is also expected to contribute to the market growth in the region.

Key Players Covered

The report includes the profiles of key players such as Pfizer Inc, Novartis AG, Ipsen Biopharmaceuticals Inc., Abbott, Zydus Pharmaceuticals, Inc., Amryt Pharma plc, and Sun Pharmaceutical Industries Ltd.

Key Industry Developments

• In March 2022, Ipsen Biopharmaceuticals Inc. collaborated with Phillips-Medisize, a Molex company, to design and manufacture new electronic auto injector for somatuline autogel/ somatuline depot (lanreotide) to manage the acromegaly disease.
• In June 2020, Crinetics Pharmaceuticals, Inc. received the FDA approval of MYCAPSSA. It is an oral somatostatin analog used for long-term maintenance in acromegaly patients.

In June 2019, Ipsen Biopharmaceuticals Inc. received FDA approval of somatuline depot (lanreotide) pre-filled syringe for somatuline depot (lanreotide) for the treatment of acromegaly.